Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort

被引:17
|
作者
Fainberg, Hernan P. [1 ]
Oldham, Justin M. [2 ]
Molyneaux, Philip L. [1 ,3 ,4 ]
Allen, Richard J. [5 ]
Kraven, Luke M. [5 ]
Fahy, William A. [6 ]
Porte, Joanne [7 ]
Braybrooke, Rebecca [7 ]
Saini, Gauri [7 ]
Karsdal, Morten A. [9 ]
Leeming, Diane J. [9 ]
Sand, Jannie M. B. [9 ]
Triguero, Isaac [8 ,10 ]
Oballa, Eunice [3 ,4 ,6 ]
Wells, Athol U. [1 ]
Renzoni, Elisabetta [1 ,3 ,4 ]
Wain, Louise, V [5 ,11 ]
Noth, Imre [12 ]
Maher, Toby M. [1 ,3 ,4 ,13 ]
Stewart, Iain D. [1 ]
Jenkins, R. Gisli [1 ,3 ,4 ]
机构
[1] Imperial Coll London, Natl Heart & Lung Inst, London, England
[2] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[3] Guys & St Thomas NHS Fdn Trust, Royal Brompton Hosp, London, England
[4] Guys & St Thomas NHS Fdn Trust, Harefield Hosp, London, England
[5] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England
[6] GlaxoSmithKline Med Res Ctr, Discovery Med, Stevenage, Herts, England
[7] NIHR Biomed Res Ctr, Nottingham Resp Res Unit, Nottingham, England
[8] Univ Nottingham, Sch Comp Sci, Computat Optimisat & Learning Lab, Nottingham, England
[9] Nordic Biosci, Herlev, Denmark
[10] Univ Granada, Andalusian Inst Data Sci AndComputat Intelligence, Granada, Spain
[11] Glenfield Hosp, Leicester Resp Biomed Res Ctr, Natl Inst Hlth Res, Leicester, Leics, England
[12] Univ Virginia, Pulm & Crit Care Med, Charlottesville, VA USA
[13] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
来源
LANCET DIGITAL HEALTH | 2022年 / 4卷 / 12期
基金
英国医学研究理事会;
关键词
PHASE-3; TRIAL; DOUBLE-BLIND; PIRFENIDONE; IPF; MORTALITY;
D O I
10.1016/S2589-7500(22)00173-X
中图分类号
R-058 [];
学科分类号
摘要
Background Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease with a variable clinical trajectory. Decline in forced vital capacity (FVC) is the main indicator of progression; however, missingness prevents long-term analysis of patterns in lung function. We aimed to identify distinct clusters of lung function trajectory among patients with idiopathic pulmonary fibrosis using machine learning techniques. Methods We did a secondary analysis of longitudinal data on FVC collected from a cohort of patients with idiopathic pulmonary fibrosis from the PROFILE study; a multicentre, prospective, observational cohort study. We evaluated the imputation performance of conventional and machine learning techniques to impute missing data and then analysed the fully imputed dataset by unsupervised clustering using self-organising maps. We compared anthropometric features, genomic associations, serum biomarkers, and clinical outcomes between clusters. We also performed a replication of the analysis on data from a cohort of patients with idiopathic pulmonary fibrosis from an independent dataset, obtained from the Chicago Consortium. Findings 415 (71%) of 581 participants recruited into the PROFILE study were eligible for further analysis. An unsupervised machine learning algorithm had the lowest imputation error among tested methods, and self-organising maps identified four distinct clusters (1-4), which was confirmed by sensitivity analysis. Cluster 1 comprised 140 (34%) participants and was associated with a disease trajectory showing a linear decline in FVC over 3 years. Cluster 2 comprised 100 (24%) participants and was associated with a trajectory showing an initial improvement in FVC before subsequently decreasing. Cluster 3 comprised 113 (27%) participants and was associated with a trajectory showing an initial decline in FVC before subsequent stabilisation. Cluster 4 comprised 62 (15%) participants and was associated with a trajectory showing stable lung function. Median survival was shortest in cluster 1 (2 center dot 87 years [IQR 2 center dot 29-3 center dot 40]) and cluster 3 (2 center dot 23 years [1 center dot 75-3 center dot 84]), followed by cluster 2 (4 center dot 74 years [3 center dot 96-5 center dot 73]), and was longest in cluster 4 (5 center dot 56 years [5 center dot 18-6 center dot 62]). Baseline FEV1 to FVC ratio and concentrations of the biomarker SP-D were significantly higher in clusters 1 and 3. Similar lung function clusters with some shared anthropometric features were identified in the replication cohort. Interpretation Using a data-driven unsupervised approach, we identified four clusters of lung function trajectory with distinct clinical and biochemical features. Enriching or stratifying longitudinal spirometric data into clusters might optimise evaluation of intervention efficacy during clinical trials and patient management. Copyright (c) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
引用
收藏
页码:E862 / E872
页数:11
相关论文
共 50 条
  • [31] Long-term Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Is Independent of Baseline Forced Vital Capacity
    Noble, Paul
    Albera, Carlo
    Kirchgaessler, Klaus-Uwe
    Gilberg, Frank
    Petzinger, Ute
    Costabel, Ulrich
    CHEST, 2016, 150 (04) : 538A - 538A
  • [32] Insight into the relationship between forced vital capacity and transfer of the lungs for carbon monoxide in patients with idiopathic pulmonary fibrosis
    Soumagne, Thibaud
    Quetantb, Sebastien
    Guillien, Alicia
    Falque, Loic
    Hess, David
    Aguilaniu, Bernard
    Degano, Bruno
    RESPIRATORY MEDICINE AND RESEARCH, 2023, 84
  • [33] Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone
    Kono, Masato
    Nakamura, Yutaro
    Enomoto, Noriyuki
    Saito, Go
    Koyanagi, Yu
    Miyashita, Koichi
    Tsutsumi, Akari
    Kobayashi, Takeshi
    Yasui, Hideki
    Hozumi, Hironao
    Karayama, Masato
    Suzuki, Yuzo
    Furuhashi, Kazuki
    Miki, Yoshihiro
    Hashimoto, Dai
    Fujisawa, Tomoyuki
    Inui, Naoki
    Suda, Takafumi
    Nakamura, Hidenori
    RESPIRATORY INVESTIGATION, 2019, 57 (06) : 552 - 560
  • [34] Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study
    Adams, Colin J.
    Shapera, Shane
    Ryerson, Christopher J.
    Assayag, Deborah
    Johannson, Kerri A.
    Fell, Charlene D.
    Morisset, Julie
    Manganas, Helene
    Kolb, Martin
    Hambly, Nathan
    Cox, Gerard
    Khalil, Nasreen
    Marcoux, Veronica
    Wilcox, Pearce G.
    To, Teresa
    Sadatsafavi, Mohsen
    Halayko, Andrew J.
    Gershon, Andrea
    Garlick, Kristopher
    Fisher, Jolene H.
    RESPIRATORY MEDICINE, 2022, 191
  • [35] Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis
    Lasseniusa, Mariann I.
    Toppila, Iiro
    Pontynen, Nora
    Kasslin, Laura
    Kaunisto, Jaana
    Kilpelainen, Maritta
    Laitinen, Tarja
    EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2020, 7 (01):
  • [36] Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis
    Paterniti, Miya O.
    Bi, Youwei
    Rekic, Dinko
    Wang, Yaning
    Karimi-Shah, Banu A.
    Chowdhury, Badrul A.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (09) : 1395 - 1402
  • [37] Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib
    Mondoni, Michele
    Varone, Francesco
    Alfano, Fausta
    Muscato, Giuseppe
    Conti, Caterina
    Saderi, Laura
    Iovene, Bruno
    Di Marco, Fabiano
    Vancheri, Carlo
    Richeldi, Luca
    Centanni, Stefano
    Sotgiu, Giovanni
    ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (07): : 464 - 466
  • [38] First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
    Wim A. Wuyts
    Martin Kolb
    Susanne Stowasser
    Wibke Stansen
    John T. Huggins
    Ganesh Raghu
    Lung, 2016, 194 : 739 - 743
  • [39] Improvement In Forced Vital Capacity (FVC) With Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (ipf): Results From The Inpulsis Trials
    Flaherty, K. R.
    Kolb, M.
    Vancheri, C.
    Tang, W.
    Conoscenti, C. S.
    Richeldi, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [40] Effect Of Nintedanib On Decline In Forced Vital Capacity (FVC) Over Time In The Inpulsis® Trials In Patients With Idiopathic Pulmonary Fibrosis
    Maher, T. M.
    Flaherty, K. R.
    Azuma, A.
    Cottin, V.
    Stansen, W.
    Quaresma, M.
    Wells, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193